Table 2.

Information on the trials involving sorafenib included in Table 1

Reference	[10]	[46]	[58]	[59]	[60]
Trial keyword	SHARP	Asia-Pacific	Japanese	REFLECT	IMbrave150
Trial arms	Sorafenib VS placebo	Sorafenib VS placebo	Safety profile of sorafenib, HCC VS RCC	Lenvatinib VS sorafenib	Atezolizumab plus bevacizumab VS sorafenib
Number of patients in sorafenib group	297	149	70	475	156
Year of data publish	2008	2009	2014	2018	2020
Trial phase	III	III	Real-life conditions	III	III
Trial number	NCT00105443	NCT00492752	-	NCT01761266	NCT03434379
Patients enrolled	121 centers, 21 countries in Europe, North America, South America, Australasia	23 centers in China, South Korea, Taiwan	Japanese HCC patients	154 sites in 20 countries throughout the Asia-Pacific region, Europe, North America	Asia excluding Japanese v.s. the rest of the world